Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate

PLoS One. 2007 Oct 10;2(10):e1023. doi: 10.1371/journal.pone.0001023.

Abstract

Background: P. falciparum gametocytes may persist after treatment with sulphadoxine-pyrimethamine (SP) plus artesunate (AS) and contribute considerably to malaria transmission. We determined the efficacy of SP+AS plus a single dose of primaquine (PQ, 0.75 mg/kg) on clearing gametocytaemia measured by molecular methods.

Methodology: The study was conducted in Mnyuzi, an area of hyperendemic malaria in north-eastern Tanzania. Children aged 3-15 years with uncomplicated P. falciparum malaria with an asexual parasite density between 500-100,000 parasites/microL were randomized to receive treatment with either SP+AS or SP+AS+PQ. P. falciparum gametocyte prevalence and density during the 42-day follow-up period were determined by real-time nucleic acid sequence-based amplification (QT-NASBA). Haemoglobin levels (Hb) were determined to address concerns about haemolysis in G6PD-deficient individuals.

Results: 108 individuals were randomized. Pfs25 QT-NASBA gametocyte prevalence was 88-91% at enrolment and decreased afterwards for both treatment arms. Gametocyte prevalence and density were significantly lower in children treated with SP+AS+PQ. On day 14 after treatment 3.9% (2/51) of the SP+AS+PQ treated children harboured gametocytes compared to 62.7% (32/51) of those treated with SP+AS (p<0.001). Hb levels were reduced in the week following treatment with SP+AS+PQ and this reduction was related to G6PD deficiency. The Hb levels of all patients recovered to pre-treatment levels or greater within one month after treatment.

Conclusions: PQ clears submicroscopic gametocytes after treatment with SP+AS and the persisting gametocytes circulated at densities that are unlikely to contribute to malaria transmission. For individuals without severe anaemia, addition of a single dose of PQ to an efficacious antimalarial drug combination is a safe approach to reduce malaria transmission following treatment.

Trial registration: Controlled-Trials.com ISRCTN61534963.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Animals
  • Antimalarials / administration & dosage*
  • Artemisinins / therapeutic use*
  • Artesunate
  • Child
  • Child, Preschool
  • Drug Combinations
  • Female
  • Humans
  • Malaria / drug therapy*
  • Malaria, Falciparum / drug therapy*
  • Male
  • Plasmodium falciparum / metabolism*
  • Primaquine / therapeutic use*
  • Pyrimethamine / therapeutic use*
  • Sesquiterpenes / therapeutic use*
  • Sulfadoxine / therapeutic use*
  • Tanzania
  • Treatment Outcome

Substances

  • Antimalarials
  • Artemisinins
  • Drug Combinations
  • Sesquiterpenes
  • fanasil, pyrimethamine drug combination
  • Artesunate
  • Sulfadoxine
  • Primaquine
  • Pyrimethamine

Associated data

  • ISRCTN/ISRCTN61534963